Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Black and American Indian patients are less likely to have elevated CA-125 levels compared with White patients.

Real Housewives of Beverly Hills alum Teddi Mellencamp shared an update on the side effects of her cancer treatments, less ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...